40046-95-5

Basic information

• Product Name: Benzenamine, N,N-diethyl-4-[(phenylimino)methyl]-
• CAS NO: 40046-95-5
• Molecular Formula: C17H20N2
• Molecular Weight: 252.359
• Mol File: 40046-95-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzenamine, N,N-diethyl-4-[(phenylimino)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, N,N-diethyl-4-[(phenylimino)methyl]-(40046-95-5)
• EPA Substance Registry System: Benzenamine, N,N-diethyl-4-[(phenylimino)methyl]-(40046-95-5)

Safety Data

• Hazardous Substances Data: 40046-95-5(Hazardous Substances Data)

Upstream product

• 120-21-8 4-Diethylaminobenzaldehyde 
• 62-53-3 aniline 

Downstream Products

• 1448449-90-8 4-((Z)-((Z)-3-benzylideneisobenzofuran-1(3H)-ylidene)methyl)-N,N-diethylaniline 
• 1426152-03-5 N-(4-(diethylamino)benzyl)-4-methoxy-N-phenylbenzenesulfonamide 
• 940362-30-1 N,N-diethyl-4-((phenylamino)methyl)aniline 
• 81347-62-8 Diethyl-{4-[(Z)-phenyliminomethyl]-phenyl}-amine; compound with diphenyl-phosphinic acid 
• 34200-53-8 2-[4-(diethylamino)benzylidene]-1H-indane-1,3(2H)-dione 
• 40046-71-7 2-(4-diethylamino-phenyl)-3,6-diphenyl-2,3-dihydro-[1,3,5]oxadiazin-4-one 
• 40046-70-6 1-benzoyl-4-(4-diethylamino-phenyl)-3-phenyl-[1,3]diazetidin-2-one 
• 23833-47-8 trans-1,2-Bis-(4'-diaethylamino-stilben-4-yl)-acetylen 
• 23820-49-7 trans-4-<4-Diethylamino-styryl-biphenyl 
• 16178-17-9 4-[4-(4,5-diphenyl-oxazol-2-yl)-styryl]-N,N-diethyl-aniline 

Relevant articles and documents

Trisubstituted sulfonamides: A new chemotype for development of potent and selective CB2 receptor inverse agonists

An extensive exploration of the structure-activity relationship of a trisubstituted sulfonamide series led to the identification of 39, which is a potent and selective CB2 receptor inverse agonist [K i(CB2) = 5.4 nM, and Ki(CB1) = 500 nM]. The functional properties measured by cAMP assays indicated that the selected compounds were CB2 inverse agonists with high potency values (for 34, EC50 = 8.2 nM, and for 39, EC50 = 2.5 nM). Furthermore, an osteoclastogenesis bioassay indicated that trisubstituted sulfonamide compounds showed great inhibition of osteoclast formation.